Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease

Wiener Klinische Wochenschrift

Volumn 125, Issue 15-16, 2013, Pages 439-447

  Anghel, Rodica ^a   Bachmann, Alexander ^b   Bekşac, Meral ^c   Brodowicz, Thomas ^d   Finek, Jindřich ^e   Komadina, Radko ^f   Krzemieniecki, Krzysztof ^g   Lang, Istvan ^h   Marencak, Jozef ⁱ   Von Moos, Roger ^j   Pecherstorfer, Martin ^d   Rordorf, Tamara ^k   Vrbanec, Damir ^l   Zielinski, Christoph ^d  

^a Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti   (Romania)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c ANKARA UNIVERSITY   (Turkey)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e Faculty Hospital   (Czech Republic)

^f General and Teaching Hospital Celje   (Slovenia)

^g JAGIELLONIAN UNIVERSITY   (Poland)

^h NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

ⁱ Urology Clinic   (Slovakia)

^j KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^l KBC Zagreb   (Croatia)

more..

Author keywords

Anti resorptive agents; Bisphosphonates; Denosumab; Metastatic breast cancer; Metastatic prostate cancer

Indexed keywords

DENOSUMAB; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ADVANCED CANCER; BONE DISEASE; BONE METASTASIS; BONE REMODELING; BREAST CANCER; CANCER PREVENTION; CASTRATION RESISTANT PROSTATE CANCER; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; NEPHROTOXICITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; DIPHOSPHONATES; EVIDENCE-BASED MEDICINE; HUMANS; IMIDAZOLES; INTERNATIONALITY; PALLIATIVE CARE; TREATMENT OUTCOME;

EID: 84883349285     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-013-0385-4     Document Type: Review

References (36)

1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165-76.
2. Kinnane N. Burden of bone disease. Eur J Oncol Nurs. 2007;11(Suppl 2):S28-31.
3. Pockett RD, Castellano D, McEwan P, Oglesby A, Barber BL, Chung K. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl). 2010;19(6):755-60.
4. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumours: a randomised, Phase III, double-blind, placebo-controlled trial. Cancer. 2004;100(12):2613-21.
5. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomised, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458-68.
6. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomised, placebo-controlled trials. Cancer. 2000;88(5):1082-90.
7. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modelling and remodelling. Arch Biochem Biophys. 2008;473(2):139-46.
8. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001;142(12):5050-5.
9. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol. 2005;5(6):618-25.
10. O'Brien EA, Williams JH, Marshall MJ. Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. Biochem Biophys Res Commun. 2000;274(2):281-90.
11. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol. 2000;157(2):435-48.
12. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309-19.
13. Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology. 2000;141(12):4768-76.
14. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584-93.
15. Van Beek ER, Lowik CW, Papapoulos SE. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone. 2002;30(1):64-70.
16. Alakangas A, Selander K, Mulari M, Halleen J, Lehenkari P, Monkkonen J, et al. Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int. 2002;70(1):40-7.
17. Coleman R, Abrahamsson P-A, Hadhi P. editors. Handbook of cancer-related bone disease. UK:BioScientifica; 2000.
18. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo-controlled trial. J Clin Oncol. 2005;23(15):3314-21.
19. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomised, double-blind, multicenter, comparative trial. Cancer. 2003;98(8):1735-44.
20. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003;14(9):1399-405.
21. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, Boer RH de, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double-blind study. J Clin Oncol. 2010;28(35):5132-9.
22. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879-82.
23. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813-22.
24. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase III, randomised, placebo-controlled trial. Lancet. 2012;379(9810):39-46.
25. Van den Wyngaert T, Huizing MT, Vermorken JB. Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol. 2007;19(4):315-22.
26. Van den Wyngaert T, Wouters K, Huizing MT, Vermorken JB. RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? Suppor Care Cancer. 2011;19(12):2035-40.
27. Guarneri V, Donati S, Nicolini M, Giovannelli S, D'Amico R, Conte PF. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years. Oncologist. 2005;10(10):842-8.
28. Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100(1):36-43.
29. Moos R von, Caspar CB, Steiner R, Angst R, Inauen R, Schmieding K, et al. Long-term renal safety profile of ibandronate 6 mg infused over 15 min. Onkologie. 2010;33(8-9):447-50.
30. Body JJ, Diel IJ, Tripathy D, Bergstrom B. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. Eur J Cancer Care (Engl). 2006;15(3):299-302.
31. Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27(7):1471-9.
32. Xgeva (Denosumab) Summary of Product Characteristics. European Medicines Agency [updated 11/09/2012 cited (2012)]. http://www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/human/medicines/002173/human-med-001463.jsp&mid= WC0b01ac058001d124. Accessed: 17. Sept. 2012.
33. Van Poznak CH, Von Roenn JH, Temin S. American society of clinical oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer. J Oncol Pract. 2011;7(2):117-21.
34. Network NCC. NCCN clinical practice guidelines in concology: prostate cancer, version 4.2011. (2011). http://www.nccn.org. Accessed: 20. Feb. 2012.
35. Summary of product characteristics. European Medicines Agency. http://www.ema.europa.eu/ema/. Accessed: 18. Sept. 2012.
36. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008;19(3):420-32.